Maria Baggstrom is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 105 publications with 2,096 citations (h-index 21); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 15 Apr 2025.
Clinical trials
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
- 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab
Sponsor: Washington University School of Medicine
- Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Cancer Epidemiology Biomarkers & Prevention
2024 - Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution
Journal of Medical Internet Research
2023 - Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics
2022 - Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology
2022 - A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
Journal of Thoracic Disease
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Randall Bateman, MD
Washington University in St. Louis
Janet McGill, MD
Washington University in St. Louis
Robert Carney, MD
Washington University in St. Louis
David Clifford, MD
Washington University in St. Louis
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”